Ramantamig not checked

Johnson & Johnson (Janssen) · JNJ-79635322 · BCMAxGPRC5DxCD3

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
9 active
9 in total · 6 in the EU
Targets
—
None known yet

What this is

How it works
An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
How it’s given
“Ramantamig will be administered as subcutaneous (SC) injection.”In the company’s words, NCT07903272 on ClinicalTrials.gov
Tested for
Multiple Myeloma (8 trials), Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
Main trialPhase 3
“The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.”In the company’s words, NCT07258511 on ClinicalTrials.gov
Other names
JNJ-79635322 · BCMAxGPRC5DxCD3

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up9

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 12 Dec 2028 A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3Recruiting 29 Apr 2029 A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3Recruiting 4 Sep 2030 A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Phase 3Not yet recruiting 11 Jan 2037 A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Phase 2Active, not recruiting 14 Jun 2027 A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2Recruiting 31 Dec 2027 A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Phase 2Recruiting 30 May 2030 A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Phase 1Recruiting 19 Apr 2027 A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Phase 1Recruiting 2 Jan 2029 A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ramantamig

Following is part of Solo: you see every change to Ramantamig the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in